JOJohn O'DOnnell

John O'DOnnell

*This is an algorithmically generated author record based on publicly available information.

John O'DOnnell has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Maiken Nedergaard

    University of Copenhagen

    5 shared publications
  • Nicholas John Maragakis

    Department of Neurology, Johns Hopkins University School of Medicine

    4 shared publications
  • Angelo C. Lepore

    Department of Neuroscience, Thomas Jefferson University Medical College, Philadelphia, Pennsylvania, United States of America

    3 shared publications
  • Fengfei Ding

    Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, NY 14642, USA. Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    3 shared publications
  • Britta Rauck

    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland

    2 shared publications
  • Douglas Zeppenfeld

    Division of Glial Disease and Therapeutics, Center for Translational Neuromedicine, Department of Neurosurgery, University of Rochester Medical Center, Rochester, New York 14642

    2 shared publications

Latest Publications

  • Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease

    by Peter S. Myers, John L. O'DOnnell, Joshua J. Jackson, Christina N. Lessov-Schlaggar, Rebecca L. Miller, Erin R. Foster, Carlos Cruchaga, Bruno A. Benitez, Paul T. Kotzbauer, Joel S. Perlmutter, et al.

    Background and Objectives People with Parkinson disease (PD) commonly experience cognitive decline, which may relate to increased α-synuclein, tau, and β-amyloid accumulation. This study examines whether the different proteins predict longitudinal cognitive decline in PD. Methods All participants (PD n = 152, controls n = 52) were part of a longitudinal study and completed a lumbar puncture for CSF protein analysis (α-synuclein, total tau [tau], and β-amyloid42 [β-amyloid]), a β-amyloid PET scan, and/or provided a blood sample for APOE genotype (ε4+, ε4−), which is a risk factor for β-amyloid accumulation. Participants also had comprehensive, longitudinal clinical assessments of overall cognitive function and dementia status, as well as cognitive testing of attention, language, memory, and visuospatial and executive function. We used hierarchical linear growth models to examine whether the different protein metrics predict cognitive change and multivariate Cox proportional hazard models to predict time to dementia conversion. Akaike information criterion was used to compare models for best fit. Results Baseline measures of CSF β-amyloid predicted decline for memory (p = 0.04) and overall cognitive function (p = 0.01). APOE genotypes showed a significant group (ε4+, ε4−) effect such that ε4+ individuals declined faster than ε4− individuals in visuospatial function (p = 0.03). Baseline β-amyloid PET significantly predicted decline in all cognitive measures (all p ≤ 0.004). Neither baseline CSF α-synuclein nor tau predicted cognitive decline. All 3 β-amyloid-–related metrics (CSF, PET, APOE) also predicted time to dementia. Models with β-amyloid PET as a predictor fit the data the best. Discussion Presence or risk of β-amyloid accumulation consistently predicted cognitive decline and time to dementia in PD. This suggests that β-amyloid has high potential as a prognostic indicator and biomarker for cognitive changes in PD.


  • Top Cited Papers

    Changes in the composition of brain interstitial ions control the sleep-wake cycle

    by Fengfei Ding, John O’donnell, Qiwu Xu, Ning Kang, Nanna Goldman, Maiken Nedergaard

    Sleep induction through ion changes: How do we switch from sleep to arousal and back? Ding et al. found that a combination of modulatory neurotransmitters influenced the levels of extracellular ions in the brain (see the Perspective by Landolt and Holst). This influence was not driven by changes in local neuronal firing, suggesting direct effects of the neuromodulators on extracellular ion composition. However, these changes in interstitial ion levels could switch a brain from wakefulness to sleep. Changes in extracellular ions may thus be a cause, rather than a consequence, of sleep/wake-dependent changes in neuronal activity. Science , this issue p. 550 ; see also p. 517


  • Distinct Functional States of Astrocytes During Sleep and Wakefulness: Is Norepinephrine the Master Regulator?

    by John O’donnell, Fengfei Ding, Maiken Nedergaard

    Astrocytes are the chief supportive cells in the central nervous system, but work over the past 20 years have documented that astrocytes also contribute to complex neural processes, such as working memory. Recent discoveries of norepinephrine-mediated astrocytic Ca2+ responses have raised the possibility that astrocytic activity in the adult brain is driven by global responses to changes in behavioral state. Moreover, analysis of the interstitial space volume suggests that astrocytes may undergo changes in cell volume in response to activation of norepinephrine receptors. This review will focus on what is known about astrocytic functions within the nervous system and how these functions interrelate with rapid changes in behavioral state mediated by norepinephrine signaling.


  • α1-Adrenergic receptors mediate coordinated Ca2+ signaling of cortical astrocytes in awake, behaving mice

    by Fengfei Ding, John O’donnell, Alexander S. Thrane, Douglas Zeppenfeld, Hongyi Kang, Lulu Xie, Fushun Wang, Maiken Nedergaard


  • Top Cited Papers

    Sleep Drives Metabolite Clearance from the Adult Brain

    by Lulu Xie, Hongyi Kang, Qiwu Xu, Michael J. Chen, Yonghong Liao, Meenakshisundaram Thiyagarajan, John O’donnell, Daniel J. Christensen, Charles Nicholson, Jeffrey J. Iliff, et al.

    Taking Out the Trash: The purpose of sleep remains mysterious. Using state-of-the-art in vivo two-photon imaging to directly compare two arousal states in the same mouse, Xie et al. (p. 373 ; see the Perspective by Herculano-Houzel ) found that metabolic waste products of neural activity were cleared out of the sleeping brain at a faster rate than during the awake state. This finding suggests a mechanistic explanation for how sleep serves a restorative function, in addition to its well-described effects on memory consolidation.


  • Norepinephrine: A Neuromodulator That Boosts the Function of Multiple Cell Types to Optimize CNS Performance

    by John O’donnell, Douglas Zeppenfeld, Evan McConnell, Salvador Pena, Maiken Nedergaard

    Norepinephrine (NE) is a neuromodulator that in multiple ways regulates the activity of neuronal and non-neuronal cells. NE participates in the rapid modulation of cortical circuits and cellular energy metabolism, and on a slower time scale in neuroplasticity and inflammation. Of the multiple sources of NE in the brain, the locus coeruleus (LC) plays a major role in noradrenergic signaling. Processes from the LC primarily release NE over widespread brain regions via non-junctional varicosities. We here review the actions of NE in astrocytes, microglial cells, and neurons based on the idea that the overarching effect of signaling from the LC is to maximize brain power, which is accomplished via an orchestrated cellular response involving most, if not all cell types in CNS.


  • Open Access

    Human Glial-Restricted Progenitor Transplantation into Cervical Spinal Cord of the SOD1G93A Mouse Model of ALS

    by Angelo C. Lepore, John O'DOnnell, Andrew S. Kim, Timothy Williams, Alicia Tuteja, Mahendra S. Rao, Linda L. Kelley, James T. Campanelli, Nicholas J. Maragakis

    Cellular abnormalities are not limited to motor neurons in amyotrophic lateral sclerosis (ALS). There are numerous observations of astrocyte dysfunction in both humans with ALS and in SOD1G93A rodents, a widely studied ALS model. The present study therapeutically targeted astrocyte replacement in this model via transplantation of human Glial-Restricted Progenitors (hGRPs), lineage-restricted progenitors derived from human fetal neural tissue. Our previous findings demonstrated that transplantation of rodent-derived GRPs into cervical spinal cord ventral gray matter (in order to target therapy to diaphragmatic function) resulted in therapeutic efficacy in the SOD1G93A rat. Those findings demonstrated the feasibility and efficacy of transplantation-based astrocyte replacement for ALS, and also show that targeted multi-segmental cell delivery to cervical spinal cord is a promising therapeutic strategy, particularly because of its relevance to addressing respiratory compromise associated with ALS. The present study investigated the safety and in vivo survival, distribution, differentiation, and potential efficacy of hGRPs in the SOD1G93A mouse. hGRP transplants robustly survived and migrated in both gray and white matter and differentiated into astrocytes in SOD1G93A mice spinal cord, despite ongoing disease progression. However, cervical spinal cord transplants did not result in motor neuron protection or any therapeutic benefits on functional outcome measures. This study provides an in vivo characterization of this glial progenitor cell and provides a foundation for understanding their capacity for survival, integration within host tissues, differentiation into glial subtypes, migration, and lack of toxicity or tumor formation.


  • Reduction in expression of the astrocyte glutamate transporter, GLT1, worsens functional and histological outcomes following traumatic spinal cord injury

    by Angelo C. Lepore, John O'DOnnell, Andrew S. Kim, Eun Ju Yang, Alisha Tuteja, Amanda Haidet‐Phillips, Colin P. O'BAnion, Nicholas J. Maragakis

    The astrocyte glutamate transporter, GLT1, is responsible for the vast majority of glutamate uptake in the adult central nervous system (CNS), thereby regulating extracellular glutamate homeostasis and preventing excitotoxicity. Glutamate dysregulation plays a central role in outcome following traumatic spinal cord injury (SCI). To determine the role of GLT1 in secondary cell loss following SCI, mice heterozygous for the GLT1 astrocyte glutamate transporter (GLT1+/−) and wild‐type mice received thoracic crush SCI. Compared with wild‐type controls, GLT1+/− mice had an attenuated recovery in hindlimb motor function, increased lesion size, and decreased tissue sparing. GLT1+/− mice showed a decrease in intraspinal GLT1 protein and functional glutamate uptake compared with wild‐type mice, accompanied by increased apoptosis and neuronal loss following crush injury. These results suggest that astrocyte GLT1 plays a role in limiting secondary cell death following SCI, and also show that compromise of key astrocyte functions has significant effects on outcome following traumatic CNS injury. These findings also suggest that increasing intraspinal GLT1 expression may represent a therapeutically relevant target for SCI treatment.


  • Spatial and temporal changes in promoter activity of the astrocyte glutamate transporter GLT1 following traumatic spinal cord injury

    by Angelo C. Lepore, John O'Donnell, Joseph F. Bonner, Courtney Paul, Mark E. Miller, Britta Rauck, Robert A. Kushner, Jeffrey D. Rothstein, Itzhak Fischer, Nicholas J. Maragakis

    After traumatic spinal cord injury (SCI), there is an opportunity for preserving function by attenuating secondary cell loss. Astrocytes play crucial roles in the adult CNS and are responsible for the vast majority of glutamate buffering, potentially preventing excitotoxic loss of neurons and oligodendrocytes. We examined spatial and temporal changes in gene expression of the major astrocyte glutamate transporter GLT1 following moderate thoracic contusion SCI using transgenic BAC‐GLT1‐eGFP promoter reporter mice. In dorsal column white matter, total intensity of GLT1‐eGFP expression per region was significantly reduced following SCI at both lesion epicenter and at rostral and caudal areas where no tissue loss occurred. This regional decrease in GLT1 expression was due to significant loss of GLT1‐eGFP+ cells, partially accounted for by apoptosis of eGFP+/GFAP+ astrocytes in both white and gray matter. There were also decreased numbers of GLT1‐eGFP‐expressing cells in multiple gray matter regions following injury; nevertheless, there was sustained or even increased regional GLT1‐eGFP expression in gray matter as a result of up‐regulation in astrocytes that continued to express GLT1‐eGFP. Although there were increased numbers of GFAP+ cells both at the lesion site and in surrounding intact spinal cord following SCI, the majority of proliferating Ki67+/GFAP+ astrocytes did not express GLT1‐eGFP. These findings demonstrate that spatial and temporal alterations in GLT1 expression observed after SCI result from both astrocyte death and gene expression changes in surviving astrocytes. Results also suggest that following SCI a significant portion of astrocytes lacks GLT1 expression, possibly compromising the important role of astrocytes in glutamate homeostasis.


  • Peripheral hyperstimulation alters site of disease onset and course in SOD1 rats

    by Angelo C. Lepore, Christopher Tolmie, John O'Donnell, Megan C. Wright, Christine Dejea, Britta Rauck, Ahmet Hoke, Anthony R. Ignagni, Raymond P. Onders, Nicholas J. Maragakis